8 Biotechnology Stocks to Buy Now

Popular Posts: Hottest Energy Stocks Now – TPLM HK KOG SDBiggest Movers in Healthcare Stocks Now – TARO PCRX FMS INO10 Best “Strong Buy” Stocks — BITA SHPG TRGP and more Recent Posts: Hottest Financial Stocks Now – WLP HTGC CACC CG Hottest Technology Stocks Now – AYI WDC NUAN YHOO Hottest Healthcare Stocks Now – THC KND VRTX ABBV View All Posts 8 Biotechnology Stocks to Buy Now

The grades of eight biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

This week, Stemline Therapeutics, Inc. () is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). .

This week, Pharmacyclics, Inc. () is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. .

This week, Acorda Therapeutics, Inc. () pushes up from a C to a B rating. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. .

The rating of Northwest Biotherapeutics, Inc. () moves up this week, rising from a C to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. .

This week, PTC Therapeutics, Inc.’s () ratings are up from a C last week to a B. .

BioMarin Pharmaceutical () earns a B this week, jumping up from last week’s grade of C. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. .

Seattle Genetics, Inc. () boosts its rating from a C to a B this week. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. .

This is a strong week for Amgen (). The company’s rating climbs to A from the previous week’s B. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The stock has a dividend yield of 2.4%. .

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.